Amgen (Switzerland)

Economic considerations for the use of recombinant human bone morphogenetic protein‐2 in open tibial fractures in Europe: the German model

Volker Alt, Andreas Heißel

2006 · 32 Zit.

RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy

Wolfgang Eisterer, C. Hussl, Helmut Erb et al.

2010 · 7 Zit.